| 2025-03-31 | +0.1 % |
|
| 2025-03-28 | -3.44 % |
|
| 2025-03-27 | -1.13 % |
|
| 2025-03-25 | +0.84 % |
|
| 2025-03-24 | +1.01 % |
|
| 2025-03-21 | -0.04 % |
- The article discusses Hawaiian Electric Industries' significant executive pay raises despite a challenging financial year marked by a $1.4 billion net loss and ongoing lawsuits related to the Lahaina wildfire, which included the company's settlement of $1.9 billion for its role in the disaster; this news contributes to the negative sentiment surrounding PTC stock, which was down 0.04%.
The decline in PTC's stock could be attributed to concerns about executive compensation amidst poor financial performance, potential investor backlash due to ethical considerations regarding pay raises after substantial losses, and overarching uncertainties linked to the company's reputation and financial stability following the wildfire incident.
- PTC Therapeutics, Inc. (NASDAQ: PTCT) experienced a minor decline of 0.04% in stock price due to significant changes in hedge fund positions, with AlphaQuest LLC substantially reducing its holdings and analysts adjusting their ratings and price targets.
The stock's decline can be attributed to negative sentiment from hedge funds, including AlphaQuest LLC's drastic reduction of its stake, along with analysts lowering their ratings, which collectively may have raised concerns among investors.
- PTC Therapeutics, Inc. (PTC) experienced a slight decline of 0.04% in stock value, potentially influenced by recent insider sales of shares by key executives, which often raises concerns among investors regarding the company's outlook.
|
| 2025-03-20 | -0.83 % |
|
| 2025-03-19 | +0.76 % |
|
| 2025-03-18 | +0.77 % |
|
| 2025-03-17 | +1.92 % |
|
| 2025-03-14 | +1.63 % |
|
| 2025-03-12 | -0.18 % |
|
| 2025-03-11 | -2.32 % |
|
| 2025-03-10 | -1 % |
|
| 2025-03-07 | +1.3 % |
|
| 2025-03-06 | -0.37 % |
|
| 2025-03-05 | +1.72 % |
|
| 2025-03-04 | -1.32 % |
|
| 2025-02-28 | +0.54 % |
|
| 2025-02-27 | -0.17 % |
|
| 2025-02-26 | +0.19 % |
|
| 2025-02-25 | +0.09 % |
|
| 2025-02-21 | -2.48 % |
|
| 2025-02-20 | -2.45 % |
|
| 2025-02-18 | -0.18 % |
|
| 2025-02-14 | +1.89 % |
|
| 2025-02-13 | +0.82 % |
|
| 2025-02-12 | -0.84 % |
|
| 2025-02-11 | -0.26 % |
|
| 2025-02-10 | -0.35 % |
|
| 2025-02-07 | -1.51 % |
- PTC Inc. (NASDAQ:PTC) stock declined by 1.51% primarily due to abrdn plc reducing its stake by 9.3% and the company reporting earnings that missed analysts' expectations, which led to concerns about its current performance.
- PTC (NASDAQ:PTC) stock fell by 1.51% after Citigroup reduced its price target from $200.00 to $195.00 and assigned a "neutral" rating, which reflects a more cautious outlook on the company's performance, compounded by a recent earnings miss.
- PTC Therapeutics, Inc. (NASDAQ:PTCT) stock fell by 1.51% following an update from Cantor Fitzgerald, which lowered its FY2025 earnings per share estimates from ($2.84) to ($3.26), contributing to investor concerns about the company's financial outlook.
- PTC Therapeutics (PTCT) stock decreased by 1.51% following the company's recent earnings report that revealed a loss, despite beating analysts' expectations, as well as notable insider sales and mixed analyst ratings. The decline may be attributed to profit-taking by investors after positive earnings news, increasing concerns over the company's financial health given its negative earnings per share, and ongoing market volatility.
- PTC Inc. (NASDAQ:PTC) stock declined by 1.51% following the company's fourth-quarter earnings report, which revealed earnings per share of $0.79, missing the consensus estimate of $0.91 by $0.12, indicating weaker financial performance than analysts expected.
|
| 2025-02-06 | -9.56 % |
|
| 2025-02-05 | -0.69 % |
|
| 2025-02-04 | +0.63 % |
|
| 2025-01-29 | -0.97 % |
|
| 2025-01-27 | -0.25 % |
|
| 2025-01-24 | -0.06 % |
- PTC Therapeutics (NASDAQ:PTCT) stock fell by 0.06% due to a mixed outlook on earnings revisions, with analysts adjusting future EPS estimates, as well as insider selling, which may have raised concerns among investors.
- The article discusses a significant increase in retail store closures in 2024, with 7,325 closures attributed to inflation and a shift towards online shopping, which has negatively impacted physical retailers like PTC (PTC) stocks, causing a decline of -0.06%. PTC stock likely went down due to the broader trend of increasing retail disruptions and store closures, leading to increased market uncertainty about the future of traditional retailers.
- PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a slight decline of -0.06% in its stock price following analysts' lowered earnings estimates for FY2025 and mixed ratings from various financial institutions, indicating uncertainty about the company's future performance despite some positive quarterly earnings results.
|
| 2025-01-23 | +0.61 % |
|
| 2025-01-22 | +0.02 % |
|
| 2025-01-21 | +0.06 % |
|
| 2025-01-17 | +0.44 % |
|
| 2025-01-15 | -0.07 % |
|
| 2025-01-14 | +1.69 % |
|
| 2025-01-13 | +0.02 % |
- PTC Therapeutics, Inc. (NASDAQ:PTCT) experienced a slight increase of 0.02% in its stock price, attributed to positive analyst ratings and upgrades from firms like Royal Bank of Canada and Morgan Stanley, which boosted investors' confidence in the company's prospects.
- The Supreme Court's refusal to block climate change lawsuits from states against major oil companies has sparked concerns in the fossil fuel industry, contributing to a slight increase in PTC stock by 0.02%. The stock rose likely because investors reacted positively to the potential for renewable energy initiatives gaining traction in response to increased legal pressure on oil companies regarding climate issues.
- PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a slight increase of 0.02% in its stock price, influenced by recent transactions by large investors and positive analyst ratings that have elevated their price targets for the stock.
The stock's rise can be attributed to increased investor interest and positive upgrades from several brokerages, suggesting a favorable outlook on the company's growth and future performance in the biopharmaceutical sector.
- PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a 0.02% increase in its stock price following a series of positive analyst ratings upgrades and increased hedge fund investments, reflecting growing confidence in the company's growth potential.
- The article reports that the PTC (PTC) stock rose by 0.02% amid a significant setback to the oil industry as the Supreme Court allowed lawsuits from California and other states to proceed, holding major oil companies accountable for climate change damages. The stock likely increased due to market reactions to the Supreme Court's decision, signaling potential profitability for companies focused on alternative energy solutions as fossil fuel companies face legal challenges.
|
| 2025-01-08 | +0.69 % |
|
| 2025-01-03 | +0.84 % |
|
| 2024-12-24 | +1 % |
|
| 2024-12-23 | -1.24 % |
|
| 2024-12-20 | +0.24 % |
|
| 2024-12-17 | -1.58 % |
|
| 2024-12-16 | +0.7 % |
|
| 2024-12-13 | -1.3 % |
|
| 2024-12-12 | -0.29 % |
|
| 2024-12-09 | -0.66 % |
|
| 2024-12-06 | +0.03 % |
- PTC Therapeutics (PTCT) stock rose by 0.03% following Citigroup's increase of its price target from $26.00 to $32.00, despite maintaining a "sell" rating, indicating some investor confidence in the company amid mixed analyst ratings.
- PTC Therapeutics (NASDAQ:PTCT) stock increased by 0.03% following an upgrade from StockNews.com from a "hold" to a "buy" rating, alongside several other analysts raising their price targets on the stock, which indicates positive expectations from investors.
- PTC Therapeutics (NASDAQ: PTCT) shares increased by 0.03% despite insider selling activities and a previous gap down, largely due to multiple analysts upgrading their ratings and price targets for the stock, signaling positive market sentiment.
- PTC Therapeutics (PTCT) stock saw a 0.03% increase following a series of positive analyst upgrades that raised its price targets, with Barclays, Robert W. Baird, and Royal Bank of Canada among those boosting their price objectives and ratings.
- PTC Therapeutics, Inc. (PTCT) stock increased by 0.03% following a combination of slightly lowered earnings estimates from analysts and several bullish revisions of price targets by other research firms, reflecting a mixed sentiment among investors.
|
| 2024-12-05 | -0.16 % |
- PTC Therapeutics, Inc. (NASDAQ:PTCT) stock experienced a slight decline of 0.16% despite hitting a 52-week high earlier in the trading session, primarily influenced by significant insider selling, which raised concerns among investors and may have contributed to the stock's downward movement.
- PTC Inc. (PTC) stock fell by 0.16% after Glenmede Trust Co. NA reduced its holdings in the company by 11.1%, alongside insider selling and varying institutional investments, indicating potential uncertainty about the stock's short-term prospects.
- PTC Therapeutics (PTCT) stock experienced a minor decline of -0.16% despite positive upgrades from research firms, primarily due to insider selling, with significant shares sold by executives, which could raise concerns about the company's future performance.
- PTC Therapeutics (PTCT) stock is down by 0.16% despite recent upgrades in price targets from multiple analysts, likely influenced by significant insider selling, which may raise concerns about the company's future performance.
|
| 2024-12-03 | +0.41 % |
|
| 2024-12-02 | -0.34 % |
|
| 2024-11-27 | -0.13 % |
|
| 2024-11-26 | -0.66 % |
|
| 2024-11-22 | +2.54 % |
|
| 2024-11-21 | +2.25 % |
|
| 2024-11-20 | -0.41 % |
|
| 2024-11-19 | +0.01 % |
|
| 2024-11-18 | -0.39 % |
|
| 2024-11-15 | -0.58 % |
|
| 2024-11-14 | -1.21 % |
- PTC (Plug Power, Inc.) stock declined -1.21% due to weak third-quarter earnings that missed revenue expectations, lowered full-year revenue guidance for 2024, and analysts revising price targets downwards amidst concerns about high cash burn and unclear market conditions in the hydrogen sector.
- PTC (PTC) stock experienced a decline of -1.21% as part of a broader market reaction to a significant day of earnings announcements from over 1,181 companies, where investors are closely monitoring key sectors for financial performance amid ongoing economic shifts.
- The article discusses the recent decline of PTC (PTC) stock, which fell by -1.21%, while also featuring an interview with Doug Casey about the potential implications of Donald Trump's second term for the economy and stock market. The stock's decline can be attributed to broader market trends, economic uncertainties, and investor reactions to Trump's policies, which may lead to inflation and increased government spending rather than sound economic fundamentals.
- PTC Inc. (NASDAQ:PTC) stock fell by 1.21% after Crossmark Global Holdings Inc. reduced its position in the company by 5.2%, indicating a potential decrease in investor confidence, amidst mixed ratings and target price adjustments from various analysts.
|
| 2024-11-13 | +0.28 % |
|
| 2024-11-11 | +0.65 % |
|
| 2024-11-06 | +4.24 % |
|
| 2024-11-05 | +2.02 % |
|
| 2024-11-01 | -0.16 % |
|
| 2024-10-31 | -0.81 % |
|
| 2024-10-30 | -1.33 % |
|
| 2024-10-29 | +2.21 % |
|
| 2024-10-28 | -0.94 % |
|
| 2024-10-25 | +1.84 % |
|
| 2024-10-23 | +0.36 % |
|
| 2024-10-22 | -1.02 % |
|
| 2024-10-21 | +0.22 % |
|
| 2024-10-18 | -0.44 % |
|
| 2024-10-17 | +0.4 % |
|
| 2024-10-16 | +0.26 % |
|
| 2024-10-15 | -0.8 % |
|
| 2024-10-14 | +2.49 % |
|
| 2024-10-11 | +0.34 % |
|
| 2024-10-10 | -0.66 % |
|
| 2024-10-09 | +2.02 % |
- The article notes that shares of PTC Therapeutics (NASDAQ: PTCT) experienced a 3.4% decline on Wednesday, trading at $39.38 with significantly reduced volume, after previously rising 2.02% the night before; it does not provide a specific reason for the stock's fluctuations.
The 2.02% increase may have been influenced by market sentiment, positive news, or developments related to the company's products or financial performance.
- PTC Inc. (NASDAQ:PTC) stock rose by 2.02% due to increased institutional investments, including a 7.1% stake increase from Tilia Fiduciary Partners Inc. and favorable ratings from several equities research analysts, indicating strong market confidence in the company's performance and prospects.
- PTC Therapeutics, Inc. (NASDAQ:PTCT) saw its stock increase by 2.02% following a series of positive brokerage reports that raised target prices and ratings on the stock, indicating a level of investor confidence despite recent fluctuations.
- PTC Inc. (NASDAQ:PTC) saw a 2.02% increase in its stock price, potentially influenced by Northwestern Mutual Wealth Management Co.'s significant reduction of its stake in the company, which may have prompted market reactions despite the overall decline in their holdings.
- PTC Therapeutics (PTCT) stock rose 2.02% following a significant increase in holdings by Millennium Management LLC, which boosted its stake by 123.2% in the second quarter.
|
| 2024-10-08 | +0.4 % |
|
| 2024-10-07 | -1.29 % |
- The article discusses the promising fintech stock Shift4 Payments, Inc. (NYSE: FOUR), highlighting its growth potential and resilience in the market despite recent safety and security issues disrupting the fintech sector, including a 1.29% decline in PTC stock, which may reflect investor concerns stemming from these market uncertainties and the bankruptcy of a fintech partner affecting consumer trust.
- The article discusses a recent decline in PTC India's stock, which fell by 1.29%, amidst a 3.6% downturn in the Indian market over the past week, despite the stock's annual growth and positive earnings projections. The decline in PTC's stock might be attributed to the overall poor performance of the Indian market, which is affecting investor sentiment across various sectors, including dividend stocks.
- The article does not directly discuss the reasons behind the decline of PTC (PTC) stock, which was down by -1.29%, as it primarily focuses on a commentary regarding societal trends and notable historical figures. However, the decline may be tied to external factors such as market conditions, company performance, or investor sentiment that are not covered in this excerpt.
- The PTC stock was down by 1.29% largely due to concerns over safety and security issues in the fintech sector, highlighted by a significant incident where customers were locked out of accounts following the bankruptcy of a key middleman, raising questions about the reliability of fintech partnerships with banks.
- The article discusses the growth potential of the fintech market, highlighting Fiserv, Inc. (NYSE: FI) as a strong player in this space, despite recent concerns over safety and security within the sector.
PTC (PTC) stock fell by -1.29% likely due to investor concerns regarding the safety and security issues in the fintech industry, which could impact consumer confidence and usage of fintech services.
|
| 2024-10-04 | +1.43 % |
|
| 2024-10-01 | -2.6 % |
|
